Research trends and performance of endothelin A receptor antagonist in kidney care: a bibliometric analysis

Renal Failure, Journal Year: 2025, Volume and Issue: 47(1)

Published: April 11, 2025

Endothelin A receptor antagonists (ERAs) have emerged as pivotal therapeutic agents in managing pulmonary hypertension (PH) and various kidney disorders, including chronic disease (CKD) proteinuric glomerular diseases such IgA nephropathy (IgAN) focal segmental glomerulosclerosis (FSGS). Although initially developed for applications, recent research has highlighted their renoprotective effects, expanding role nephrology. This study presents a comprehensive bibliometric analysis of global trends, key contributors, emerging applications ERAs care over the past three decades. was performed using Science Citation Index Expanded database (1992-2023). Relevant kidney-related publications were identified through specific keyword searches. Author performance assessed Y-index. ERA-related shown significant growth, particularly The United States University Groningen lead publication volume international collaborations, with H.J.L. Heerspink contributor. While PH remains dominant focus, nephrology are rapidly increasing, CKD, diabetic (DN), diseases. major milestone accelerated FDA approval sparsentan IgAN 2023, followed by full 2024 based on confirmatory efficacy data. However, challenges fluid retention cardiovascular risks remain, necessitating further investigation into optimized ERA therapies, combination strategies SGLT2 inhibitors. underscores potential treating Ongoing collaborations advancing safety, efficacy, novel strategies, supporting broader clinical application.

Language: Английский

The association of albumin-corrected anion gap and acute kidney injury in heart failure patients: a competing risk model analysis.

PubMed, Journal Year: 2025, Volume and Issue: 25(1), P. 277 - 277

Published: April 11, 2025

Language: Английский